Complete Story
10/24/2022
MSHO Featured Corporate Sponsor Assistance Programs
Adaptive Assist
Adaptive Biotechnologies understands that each patient's situation is unique. We are committed to providing guidance and support during each step of the insurance process. That's why we offer the Adaptive Assist program: to help facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by next-generation measurable residual (MRD) testing.
Natera Signatera
The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions.
At Natera, we understand that some of our patients are unable to pay for our services due to financial hardship or other circumstances. That's why, through our Compassionate Care Program, patients who qualify will pay no more than $149 per test, and may owe nothing, depending on their financial situation.
TerSera SupportSource
TerSera is committed to help remove the financial and access barriers that so often get in the way of patients who are prescribed ZOLADEX® (goserelin acetate implant) and VARUBI® (rolapitant) tablets.
To view all of MSHO's corporate members' patient assistance programs, click here.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
